Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 4.63% is 121% above its 5-year average of -21.88%, near the high end of its 5-year range (-52.29%–21.62%).
187.55% above its 12-month average of -5.29%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -18.99%.
EBITDA MARGIN
4.63%
EBITDA MARGIN AVG TTM
-5.29%
EBITDA MARGIN AVG 3Y
-14.68%
EBITDA MARGIN AVG 5Y
-21.88%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+187.55%
CURRENT VS 3Y AVG
+131.54%
CURRENT VS 5Y AVG
+121.16%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Health Catalyst, Inc.
Market Cap
$133.01M
EBITDA Margin
4.63%
TTM Avg
-5.29%
3Y Avg
-14.68%
5Y Avg
-21.88%
Market Cap
$132.98M
EBITDA Margin
5.24%
TTM Avg
5.41%
3Y Avg
5.74%
5Y Avg
10.79%
Market Cap
$130.20M
EBITDA Margin
-576.63%
TTM Avg
-556.12%
3Y Avg
-556.12%
5Y Avg
-556.12%
Market Cap
$135.95M
EBITDA Margin
-27.14%
TTM Avg
-20.66%
3Y Avg
-62.77%
5Y Avg
-50.13%
Market Cap
$137.36M
EBITDA Margin
-410.84%
TTM Avg
-410.84%
3Y Avg
-410.84%
5Y Avg
-410.84%
Market Cap
$138.03M
EBITDA Margin
-5.26%
TTM Avg
-11.06%
3Y Avg
-22.91%
5Y Avg
-20.50%
Market Cap
$127.17M
EBITDA Margin
-27378.57%
TTM Avg
-16324.37%
3Y Avg
-14117.74%
5Y Avg
-9505.20%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Health Catalyst, Inc. (HCAT) | $133.01M | 4.63% | -5.29% | -14.68% | -21.88% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $132.98M | 5.24% | 5.41% | 5.74% | 10.79% |
| LifeMD, Inc. (LFMD)vs › | $133.48M | -0.19% | -1.66% | -11.02% | -42.72% |
| Pyxis Oncology, Inc. (PYXS)vs › | $130.20M | -576.63% | -556.12% | -556.12% | -556.12% |
| Freenome, Inc. (FRNM)vs › | $136.23M | N/A | N/A | N/A | N/A |
| Organigram Global Inc. (OGI)vs › | $135.95M | -27.14% | -20.66% | -62.77% | -50.13% |
| Atrium Therapeutics, Inc. (RNA)vs › | $137.36M | -410.84% | -410.84% | -410.84% | -410.84% |
| KORU Medical Systems, Inc. (KRMD)vs › | $138.03M | -5.26% | -11.06% | -22.91% | -20.50% |
| Entera Bio Ltd. (ENTX)vs › | $127.17M | -27378.57% | -16324.37% | -14117.74% | -9505.20% |
| Alpha Cognition Inc (ACOG)vs › | $138.93M | -221.15% | -221.15% | -221.15% | -221.15% |
Gross Margin
33.5%
EBITDA Margin
4.6%
Operating Margin
-11.6%
Net Margin
-90.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -18.99% |
| 2026-03-31 | 7.59% |
| 2025-12-31 | 21.62% |
| 2025-09-30 | -6.41% |
| 2025-06-30 | -30.24% |
| 2025-03-31 | -9.89% |
| 2024-12-31 | -9.09% |
| 2024-09-30 | -4.85% |
| 2024-06-30 | -6.79% |
| 2024-03-31 | -16.44% |
| 2023-12-31 | -29.94% |
| 2023-09-30 | -18.51% |
| 2023-06-30 | -32.62% |
| 2023-03-31 | -31.35% |
| 2022-12-31 | -35.15% |
| 2022-09-30 | -47.62% |
| 2022-06-30 | -28.25% |
| 2022-03-31 | -18.44% |
| 2021-12-31 | -52.29% |
| 2021-09-30 | -51.18% |
| 2021-06-30 | -40.55% |
| 2021-03-31 | -29.55% |
| 2020-12-31 | -58.46% |
| 2020-09-30 | -39.15% |
| 2020-06-30 | -29.00% |
| 2020-03-31 | -33.75% |
| 2019-12-31 | -25.99% |
| 2019-09-30 | -46.72% |
| 2019-06-30 | -19.42% |
| 2019-03-31 | -24.94% |
| 2018-12-31 | -29.86% |
| 2018-09-30 | -43.64% |
| 2018-06-30 | -75.08% |
| 2018-03-31 | -49.95% |
